| Marshfield Clinic Inc | |
| 630 S Central Ave, Ste 106, Marshfield, Wisconsin 54449 | |
| (715) 389-5900 |
| Name | Marshfield Clinic Inc |
|---|---|
| Organization Name | Marshfield Clinic Inc |
| Location | 630 S Central Ave, Ste 106, Marshfield, Wisconsin 54449 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (715) 389-5900 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Should Gavin Newsom survive the Republican-driven attempt to oust him from office, the Democratic governor will face the prospect of paying back supporters who coalesced behind him.
Initial 2012 reimbursement rates for Medicare Advantage plans should be roughly flat, which tops the consensus expectation of a 2 percent drop, according to Citi analyst Carl McDonald. McDonald said Tuesday in a research note the rates will be hurt by cuts from the health care overhaul, but he also thinks they will benefit from an adjustment to prior estimates.
A major breakthrough in the development of stem cell-derived brain cells has put researchers on a firm path towards the first ever stem cell transplantations in people with Parkinson's disease. A new study presents the next generation of transplantable dopamine neurons produced from stem cells. These cells carry the same properties as the dopamine neurons found in the human brain.
The National Institutes of Health has awarded Rush University Medical Center approximately $5.5 million in grants to study how epigenetic changes - chemical modifications to genes that result from diet, aging, stress, or environmental exposures - define and contribute to memory formation and cognitive decline. Results from the studies could profoundly alter the way the medical community understands, diagnoses, and treats Alzheimer's disease, according to the researchers.
Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
› Verified 3 days ago
| NPI Number | 1457424491 |
| Organization Name | MARSHFIELD CLINIC INC |
| Doing Business As | MARSHFIELD CLINIC PHARMACY ON CENTRAL |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 630 S Central Ave Ste 106, Marshfield, WI 54449 |
| Phone Number | 715-389-5900 |
News Archive
Should Gavin Newsom survive the Republican-driven attempt to oust him from office, the Democratic governor will face the prospect of paying back supporters who coalesced behind him.
Initial 2012 reimbursement rates for Medicare Advantage plans should be roughly flat, which tops the consensus expectation of a 2 percent drop, according to Citi analyst Carl McDonald. McDonald said Tuesday in a research note the rates will be hurt by cuts from the health care overhaul, but he also thinks they will benefit from an adjustment to prior estimates.
A major breakthrough in the development of stem cell-derived brain cells has put researchers on a firm path towards the first ever stem cell transplantations in people with Parkinson's disease. A new study presents the next generation of transplantable dopamine neurons produced from stem cells. These cells carry the same properties as the dopamine neurons found in the human brain.
The National Institutes of Health has awarded Rush University Medical Center approximately $5.5 million in grants to study how epigenetic changes - chemical modifications to genes that result from diet, aging, stress, or environmental exposures - define and contribute to memory formation and cognitive decline. Results from the studies could profoundly alter the way the medical community understands, diagnoses, and treats Alzheimer's disease, according to the researchers.
Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
› Verified 3 days ago
| NPI Number | 1992023295 |
| Organization Name | MARSHFIELD CLINIC INC |
| Doing Business As | MARSHFIELD CLINIC PHARMACY |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 630 S. Central Ave., Suite 106, Marshfield, WI 54449 |
| Phone Number | 715-389-5900 |
News Archive
Should Gavin Newsom survive the Republican-driven attempt to oust him from office, the Democratic governor will face the prospect of paying back supporters who coalesced behind him.
Initial 2012 reimbursement rates for Medicare Advantage plans should be roughly flat, which tops the consensus expectation of a 2 percent drop, according to Citi analyst Carl McDonald. McDonald said Tuesday in a research note the rates will be hurt by cuts from the health care overhaul, but he also thinks they will benefit from an adjustment to prior estimates.
A major breakthrough in the development of stem cell-derived brain cells has put researchers on a firm path towards the first ever stem cell transplantations in people with Parkinson's disease. A new study presents the next generation of transplantable dopamine neurons produced from stem cells. These cells carry the same properties as the dopamine neurons found in the human brain.
The National Institutes of Health has awarded Rush University Medical Center approximately $5.5 million in grants to study how epigenetic changes - chemical modifications to genes that result from diet, aging, stress, or environmental exposures - define and contribute to memory formation and cognitive decline. Results from the studies could profoundly alter the way the medical community understands, diagnoses, and treats Alzheimer's disease, according to the researchers.
Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
› Verified 3 days ago
News Archive
Should Gavin Newsom survive the Republican-driven attempt to oust him from office, the Democratic governor will face the prospect of paying back supporters who coalesced behind him.
Initial 2012 reimbursement rates for Medicare Advantage plans should be roughly flat, which tops the consensus expectation of a 2 percent drop, according to Citi analyst Carl McDonald. McDonald said Tuesday in a research note the rates will be hurt by cuts from the health care overhaul, but he also thinks they will benefit from an adjustment to prior estimates.
A major breakthrough in the development of stem cell-derived brain cells has put researchers on a firm path towards the first ever stem cell transplantations in people with Parkinson's disease. A new study presents the next generation of transplantable dopamine neurons produced from stem cells. These cells carry the same properties as the dopamine neurons found in the human brain.
The National Institutes of Health has awarded Rush University Medical Center approximately $5.5 million in grants to study how epigenetic changes - chemical modifications to genes that result from diet, aging, stress, or environmental exposures - define and contribute to memory formation and cognitive decline. Results from the studies could profoundly alter the way the medical community understands, diagnoses, and treats Alzheimer's disease, according to the researchers.
Synthetic Biologics, Inc., a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that enrollment has initiated and the first patient was dosed in a Phase 1b clinical trial of SYN-004, an investigational oral beta-lactamase enzyme for the prevention of Clostridium difficile (C. difficile) infection, antibiotic-associated diarrhea and secondary antibiotic-resistant infections in patients receiving intravenous (IV) beta-lactam antibiotic therapy.
› Verified 3 days ago
Apria Healthcare Llc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1207w Veterans Pkwy 3, Marshfield, Wisconsin 54449 Phone: (715) 384-0088 | |
Marshfield Clinic Eye Center Type: Durable Medical Equipment & Medical Supplies Supplier Location: 409 N Chestnut Ave, Marshfield, Wisconsin 54449 Phone: (715) 387-1844 | |
Marshfield Clinic Inc Type: Durable Medical Equipment & Medical Supplies Supplier Location: 630 S Central Ave, Marshfield, Wisconsin 54449 Phone: (715) 389-5900 | |
Marshfield Clinic Pharmacy Type: Clinic Pharmacy Location: 1000 N Oak Ave, Marshfield, Wisconsin 54449 Phone: (715) 387-9100 | |
Marshfield Medical Center Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1000 N Oak Ave, Marshfield, Wisconsin 54449 Phone: (715) 387-5511 |